ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Endometrial Cancer
Cancer
Breast Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Barcelona, CT, ESP:

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (DO-01)

in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 179 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 126 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Barcelona, Spain and 46 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

AbbVie
AbbVie

Barcelona, Spain and 70 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 176 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Barcelona, Spain and 105 other locations

Locations recently updated

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With C...

Enrolling
Ovarian Cancer
Drug: INCB123667

Phase 2

Incyte
Incyte

Barcelona, Spain and 78 other locations

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...

Active, not recruiting
Chemotherapy-induced Thrombocytopenia
Drug: Placebo
Drug: Romiplostim

Phase 3

Amgen
Amgen

Barcelona, Catalonia, Spain and 139 other locations

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came ...

Enrolling
Ovarian Cancer Recurrent
Biological: Pembrolizumab
Biological: Bevacizumab

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 15 other locations

with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvuserti...

Active, not recruiting
Ovarian Cancer
Drug: Niraparib
Drug: Tuvusertib (M1774)

Phase 2

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Barcelona, Spain and 83 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems